-The Economist A new form of radical centrist politics is needed to tackle inequality without hurting economic growth BY THE end of the 19th century, the first age of globalisation and a spate of new inventions had transformed the world economy. But the “Gilded Age” was also a famously unequal one, with America’s robber barons and Europe’s “Downton Abbey” classes amassing huge wealth: the concept of “conspicuous consumption” dates back to 1899....

-The Business Standard Government taking steps to offer cooking gas to all rural households  India plans to provide affordable electricity to all households in the next five years, Prime Minister Manmohan Singh said today. "The Government of India aims to provide 24x7 electricity to all households in the country and affordable access to electricity in the next 5 years," he said inaugurating an International Seminar on Energy Access organised by the Ministry of...

-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at...

-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...

Fighting cancer has just become less expensive for millions of Indian patients. More than 12 years after he electrified the pharma industry by taking on powerful global giants in his quest to supply cheap anti-AIDS drugs, Cipla promoter YK Hamied is back donning the role of a price warrior. This time, his attention is on anti-cancer drugs. On Thursday, Cipla cut prices of key cancer drugs by nearly 75%, an astounding,...